Total Payments
$696,801
2024 Payments
$28,078
Companies
25
Transactions
469
Medicare Patients
1,492
Medicare Billing
$318,563
Payment Breakdown by Category
Consulting$280,662 (40.3%)
Other$253,386 (36.4%)
Travel$134,148 (19.3%)
Research$20,243 (2.9%)
Food & Beverage$6,541 (0.9%)
Education$1,820 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $280,662 | 75 | 40.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $222,276 | 61 | 31.9% |
| Travel and Lodging | $134,148 | 184 | 19.3% |
| Honoraria | $31,111 | 13 | 4.5% |
| Unspecified | $20,243 | 6 | 2.9% |
| Food and Beverage | $6,541 | 128 | 0.9% |
| Education | $1,820 | 2 | 0.3% |
Payments by Type
General
$676,558
463 transactions
Research
$20,243
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $357,738 | 248 | $0 (2024) |
| Shionogi Inc | $62,753 | 53 | $0 (2021) |
| PFIZER INC. | $51,131 | 20 | $0 (2024) |
| TETRAPHASE PHARMACEUTICALS, INC. | $41,283 | 23 | $0 (2020) |
| The Medicines Company | $33,888 | 27 | $0 (2017) |
| Astellas Pharma Global Development | $32,441 | 6 | $0 (2019) |
| Melinta Therapeutics, Inc. | $31,111 | 30 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $23,000 | 5 | $0 (2017) |
| Astellas Pharma US Inc | $15,695 | 16 | $0 (2019) |
| Bavarian Nordic A/S | $14,520 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,078 | 16 | Merck Sharp & Dohme LLC ($17,952) |
| 2023 | $34,644 | 17 | Merck Sharp & Dohme LLC ($18,896) |
| 2022 | $30,781 | 11 | Merck Sharp & Dohme LLC ($15,113) |
| 2021 | $23,805 | 11 | Merck Sharp & Dohme Corporation ($15,265) |
| 2020 | $45,797 | 24 | Merck Sharp & Dohme Corporation ($18,725) |
| 2019 | $183,171 | 162 | Merck Sharp & Dohme Corporation ($101,835) |
| 2018 | $174,525 | 123 | Merck Sharp & Dohme Corporation ($88,254) |
| 2017 | $176,000 | 105 | Merck Sharp & Dohme Corporation ($81,698) |
All Payment Transactions
469 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Meitheal Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $750.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,580.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/18/2024 | Meitheal Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $80.19 | General |
| 10/10/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $132.51 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $424.15 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/09/2024 | EAGLE PHARMACEUTICALS, INC. | Ryanodex (Drug) | Food and Beverage | In-kind items and services | $95.53 | General |
| Category: Hyperthermic Condition | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $4,864.30 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $2,264.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $566.92 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $110.42 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/07/2024 | Merck Sharp & Dohme LLC | RECARBRIO (Drug) | Travel and Lodging | In-kind items and services | $559.93 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/22/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,200.00 | General |
| 01/03/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,255.00 | General |
| 11/10/2023 | PFIZER INC. | ELREXFIO (Drug) | Travel and Lodging | In-kind items and services | $94.05 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $7,084.95 | General |
| 11/04/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $494.24 | General |
| 11/04/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $219.92 | General |
| 11/04/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $217.19 | General |
| 11/04/2023 | PFIZER INC. | — | Travel and Lodging | In-kind items and services | $217.19 | General |
| 08/24/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 08/24/2023 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 05/15/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,580.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A SUBJECT INVESTIGATOR AND SPONSOR BLINDED RANDOMIZED PLACEBO CONTROLLED MULTICENTER STUDY TO INVESTIGATE EFFICACY SAFETY AND TOLERABILITY OF VAY736 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Novartis Pharmaceuticals Corporation | $9,200 | 3 |
| Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy | Astellas Pharma Global Development | $8,025 | 1 |
| NCT05329220 | Bavarian Nordic A/S | $2,400 | 1 |
| HEOR | Astellas Pharma Global Development | $618.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 348 | 565 | $242,342 | $75,459 |
| 2022 | 9 | 325 | 540 | $240,706 | $77,814 |
| 2021 | 8 | 334 | 513 | $225,734 | $73,812 |
| 2020 | 11 | 485 | 722 | $281,626 | $91,478 |
Total Patients
1,492
Total Services
2,340
Medicare Billing
$318,563
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 121 | 309 | $189,726 | $57,558 | 30.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 36 | 36 | $17,496 | $5,298 | 30.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 45 | $12,286 | $4,530 | 36.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 27 | $7,902 | $2,976 | 37.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 25 | $8,200 | $2,823 | 34.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 22 | $3,932 | $1,480 | 37.6% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 54 | 54 | $1,188 | $381.60 | 32.1% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 15 | 15 | $614.00 | $156.60 | 25.5% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 18 | 18 | $522.00 | $139.46 | 26.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 14 | 14 | $476.00 | $116.61 | 24.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 115 | 314 | $192,796 | $60,664 | 31.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 30 | $14,580 | $4,917 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 53 | $13,250 | $4,868 | 36.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $11,228 | $4,158 | 37.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 22 | $5,850 | $2,423 | 41.4% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 40 | 40 | $880.00 | $291.11 | 33.1% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2022 | 20 | 20 | $1,000 | $214.19 | 21.4% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 21 | 21 | $714.00 | $167.46 | 23.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 12 | 12 | $408.00 | $110.51 | 27.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 121 | 284 | $174,376 | $55,502 | 31.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 50 | 50 | $24,300 | $9,105 | 37.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 37 | 51 | $12,750 | $4,598 | 36.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 19 | 19 | $7,619 | $2,232 | 29.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 13 | 15 | $3,945 | $1,621 | 41.1% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Facility | 2021 | 59 | 59 | $1,298 | $443.25 | 34.1% |
About Dr. Andrew Shorr, MD
Dr. Andrew Shorr, MD is a Pulmonary Disease healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598714438.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Shorr, MD has received a total of $696,801 in payments from pharmaceutical and medical device companies, with $28,078 received in 2024. These payments were reported across 469 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($280,662).
As a Medicare-enrolled provider, Shorr has provided services to 1,492 Medicare beneficiaries, totaling 2,340 services with total Medicare billing of $318,563. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Washington, DC
- Active Since 05/08/2006
- Last Updated 09/22/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1598714438
Products in Payments
- ZERBAXA (Drug) $117,670
- Xerava (Drug) $35,723
- Fetroja (Drug) $31,670
- CRESEMBA (Drug) $28,105
- Non-Covered $23,000
- Cresemba (Drug) $20,031
- VABOMERE (Drug) $16,930
- MINOCIN IV (Drug) $15,535
- VAY736 (Drug) $9,200
- RECARBRIO (Drug) $8,967
- Vabomere (Drug) $8,817
- PREVYMIS (Drug) $7,736
- AVYCAZ (Drug) $5,296
- Vancomycin (Drug) $4,603
- GIAPREZA (Drug) $2,841
- ACCELERATE PHENO (Device) $2,472
- DALVANCE (Drug) $2,080
- ANORO (Drug) $230.00
- Ryanodex (Drug) $95.53
- ELREXFIO (Drug) $94.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Washington
Umer Siddiqui, M.d, M.D
Pulmonary Disease — Payments: $213,275
Pulmonary Disease $213,275
Leslie Kingslow, Md, MD
Pulmonary Disease — Payments: $32,019
Pulmonary Disease $32,019
Dr. Suliman Alamro, M.d, M.D
Pulmonary Disease — Payments: $9,387
Pulmonary Disease $9,387
Dr. Karen Fagan, Md, MD
Pulmonary Disease — Payments: $8,801
Pulmonary Disease $8,801
Dr. Jacob Collen, M.d, M.D
Pulmonary Disease — Payments: $7,783
Pulmonary Disease $7,783
Dr. Steven Lerner, M.d, M.D
Pulmonary Disease — Payments: $7,003
Pulmonary Disease $7,003